한글목차

약제 요약

2형 당뇨병 치료제로 승인된 세마글루티드가 간 섬유증을 악화시키지 않으면서 NASH 개선 가능성을 높인다는 연구 결과가 AASLD 가상 간학회에서 발표되었습니다. 세마글루티드와 다른 두 가지 약물(firsocostat 및 cilofexor)을 병용하면 섬유화, 대사 및 간 건강의 다양한 지표가 크게 개선되었으며, NAFLD/NASH의 발병에는 여러 생물학적 과정이 관여하므로 많은 전문가들이 최적의 최적의 치료를 위해서는 서로 다른 작용기전을 가진 약물을 조합해야 한다고 생각합니다.

세마글루티드는 GLP-1 수용체 작용제로 인슐린 분비를 증가시켜 식욕 조절과 당과 지질 대사에 관여하는 천연 GLP-1의 작용을 모방하고, Firsocostat(GS-0976)은 아세틸 CoA 카르복시라아제(ACC) 억제제이며, ACC는 간에서 지방 생성, 즉 당에서 지방산으로의 전환에 관여합니다. Cilofexor(GS-9674)는 비스테로이드성 FXR 작용제이며, FXR은 담즙산 합성을 조절하고 지질과 당의 대사에 관여하는 FXR의 작용을 조절합니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 비알코올성 지방성 간염(NASH)용 세마글루티드에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 비알코올성 지방간염(NASH)에서 세마글루티드의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 세마글루티드 시장 평가

• 비알코올성 지방간염(NASH)에서 세마글루티드 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 비알코올성 지방간염(NASH)용 세마글루티드 시장 규모
• 각국의 시장의 분석
  • 미국의 비알코올성 지방간염(NASH)용 세마글루티드 시장 규모
  • 독일의 비알코올성 지방간염(NASH)용 세마글루티드 시장 규모
  • 영국의 비알코올성 지방간염(NASH)용 세마글루티드 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"Semaglutide Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about Semaglutide for Non-alcoholic Steatohepatitis (NASH) in the seven major markets. A detailed picture of the Semaglutide for NASH in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the Semaglutide for NASH. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Semaglutide market forecast analysis for NASH in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in NASH.

Drug Summary:

Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in NASH without worsening liver fibrosis, researchers reported at the AASLD virtual liver meeting. Combining semaglutide with two other drugs - firsocostat and cilofexor - led to greater improvements in various measures of fibrosis, metabolism, and liver health. Given the multiple biological processes that play a role in the development of NAFLD/NASH, many experts think optimal treatment may require combining drugs with different mechanisms of action.

Semaglutide is a GLP-1 receptor agonist that mimics the action of natural GLP-1, which increases insulin secretion and plays a role in appetite regulation and glucose and lipid metabolism. Firsocostat (GS-0976) is an acetyl-CoA carboxylase (ACC) inhibitor; ACC is involved in lipogenesis or conversion of carbohydrates to fatty acids in the liver. Cilofexor (GS-9674) is a nonsteroidal FXR agonist; FXR regulates bile acid synthesis and plays a role in lipid and glucose metabolism.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the Semaglutide description, mechanism of action, dosage and administration, research and development activities in Non-alcoholic Steatohepatitis (NASH).
• Elaborated details on Semaglutide regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Semaglutide research and development activities in NASH across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around Semaglutide.
• The report contains forecasted sales of Semaglutide for NASH till 2032.
• Comprehensive coverage of the late-stage emerging therapies for NASH.
• The report also features the SWOT analysis with analyst views for Semaglutide in NASH.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Semaglutide Analytical Perspective by DelveInsight

• In-depth Semaglutide Market Assessment

This report provides a detailed market assessment of Semaglutide for Non-alcoholic Steatohepatitis (NASH) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2029 to 2032.

• Semaglutide Clinical Assessment

The report provides the clinical trials information of Semaglutide for Non-alcoholic Steatohepatitis (NASH) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Non-alcoholic Steatohepatitis (NASH) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Semaglutide dominance.
• Other emerging products for NASH are expected to give tough market competition to Semaglutide and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Semaglutide in NASH.
• Our in-depth analysis of the forecasted sales data of Semaglutide from 2029 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Semaglutide in NASH.

Key Questions:

• What is the product type, route of administration and mechanism of action of Semaglutide?
• What is the clinical trial status of the study related to Semaglutide in Non-alcoholic Steatohepatitis (NASH) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Semaglutide development?
• What are the key designations that have been granted to Semaglutide for NASH?
• What is the forecasted market scenario of Semaglutide for NASH?
• What are the forecasted sales of Semaglutide in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Semaglutide for NASH?
• Which are the late-stage emerging therapies under development for the treatment of NASH?

Table of Contents

1. Report Introduction

2. Semaglutide Overview in Non-alcoholic Steatohepatitis (NASH)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. Semaglutide Market Assessment

• 5.1. Market Outlook of Semaglutide in Non-alcoholic Steatohepatitis (NASH)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of Semaglutide in the 7MM for Non-alcoholic Steatohepatitis (NASH)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of Semaglutide in the United States for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.2. Market Size of Semaglutide in Germany for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.3. Market Size of Semaglutide in France for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.4. Market Size of Semaglutide in Italy for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.5. Market Size of Semaglutide in Spain for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.6. Market Size of Semaglutide in the United Kingdom for Non-alcoholic Steatohepatitis (NASH)
  • 5.3.7. Market Size of Semaglutide in Japan for Non-alcoholic Steatohepatitis (NASH)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options